During the last session, Enveric Biosciences Inc. (NASDAQ:ENVB)’s traded shares were 5.89 million, with the beta value of the company hitting 1.39. At the end of the trading day, the stock’s price was $13.10, reflecting an intraday gain of 105.97% or $6.74. The 52-week high for the ENVB share is $187.00, that puts it down -1327.48 from that peak though still a striking 54.96% gain since the share price plummeted to a 52-week low of $5.90. The company’s market capitalization is $13.36M, and the average intraday trading volume over the past 10 days was 0.22 million shares, and the average trade volume was 85.08K shares over the past three months.
Enveric Biosciences Inc. (ENVB) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.50. ENVB has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$3.83.
Enveric Biosciences Inc. (NASDAQ:ENVB) trade information
Enveric Biosciences Inc. (ENVB) registered a 105.97% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 105.97% in intraday trading to $13.10 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is 114.05%, and it has moved by 20.29% in 30 days. Based on these gigs, the overall price performance for the year is -86.35%. The short interest in Enveric Biosciences Inc. (NASDAQ:ENVB) is 64629.99999999999 shares and it means that shorts have 0.66 day(s) to cover.
The consensus price target of analysts on Wall Street is $43.75, which implies an increase of 70.06% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $25.00 and $62.50 respectively. As a result, ENVB is trading at a discount of -377.1% off the target high and -90.84% off the low.
Enveric Biosciences Inc. (ENVB) estimates and forecasts
Statistics show that Enveric Biosciences Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Enveric Biosciences Inc. (ENVB) shares have gone down -60.30% during the last six months, with a year-to-date growth rate more than the industry average at 30.23% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -91.50% this quarter and then jump 36.20% in the quarter after that.
While earnings are projected to return -73.80% in 2022.
Enveric Biosciences Inc. is due to release its next quarterly earnings between November 23 and November 24. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Enveric Biosciences Inc. (NASDAQ:ENVB)’s Major holders
Enveric Biosciences Inc. insiders own 15.01% of total outstanding shares while institutional holders control 21.51%, with the float percentage being 25.31%. Hudson Bay Capital Management Lp is the largest shareholder of the company, while 35 institutions own stock in it. As of Mar 30, 2022, the company held over 95498.0 shares (or 9.06% of all shares), a total value of $1.58 million in shares.
The next largest institutional holding, with 39812.0 shares, is of Renaissance Technologies, LLC’s that is approximately 3.78% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $0.66 million.
Also, the Mutual Funds coming in first place with the largest holdings of Enveric Biosciences Inc. (ENVB) shares are AdvisorShares Trust-AdvisorShares Psychedelics ETF and Vanguard Total Stock Market Index Fund. Data provided on Jun 29, 2022 indicates that AdvisorShares Trust-AdvisorShares Psychedelics ETF owns about 25048.0 shares. This amounts to just over 2.38 percent of the company’s overall shares, with a $0.27 million market value. The same data shows that the other fund manager holds slightly less at 11276.0, or about 1.07% of the stock, which is worth about $0.19 million.